S2107 HCPCS Level II code: Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
S2107 is the HCPCS code for “Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
S2107Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
Short description: Adoptive immunotherapy
HCPCS · United States
Medicare details
The indicators CMS publishes with S2107 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Not payable by Medicare
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Other medical items or services
- BETOS category
- Undefined codes
- Added
- Apr 1, 2002
Where S2107 sits
- 1S codesTemporary national codes (non-Medicare)
- 2Active code S2107Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code S2107 mean?
S2107 is the HCPCS code for “Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover S2107?
CMS lists S2107’s Medicare coverage as “Not payable by Medicare” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside S2107
All S codesS2079Laparoscopic esophagomyotomy (heller type)S2080Laser-assisted uvulopalatoplasty (laup)S2083Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of salineS2095Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90 microspheresS2102Islet cell tissue transplant from pancreas; allogeneicS2103Adrenal tissue transplant to brainS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2115Osteotomy, periacetabular, with internal fixationS2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing, including acetabular and femoral componentsS2120Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitationS2140Cord blood harvesting for transplantation, allogeneic